Padcev (enfortumab vedotin)

pCPA File Number: 22944

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.

Sponsor/Manufacturer:

Seagen Canada Inc.

CDA-AMC Project Number:

PC0353-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable